1.01-16x9-GVB-Biopharma-KK-123911 (1).png
22nd Century Group (XXII) Adds 1,200 Drug Store Locations Selling VLN® in Five States
12. September 2023 07:00 ET | 22nd Century Group, Inc
BUFFALO, N.Y., Sept. 12, 2023 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: XXII), a leading biotechnology company focused on utilizing advanced plant technologies to improve health and...
1.01-16x9-GVB-Biopharma-KK-123911 (1).png
22nd Century Group Initiates Strategic Alternatives Process for Its Tobacco Assets
05. September 2023 07:00 ET | 22nd Century Group, Inc
BUFFALO, N.Y., Sept. 05, 2023 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NASDAQ: XXII) (the “Company”) today announced that its Board of Directors, after consultation with its financial and legal...
1.01-16x9-GVB-Biopharma-KK-123911 (1).png
22nd Century Group (XXII) Reports Second Quarter 2023 Financial Results
14. August 2023 06:00 ET | 22nd Century Group, Inc
Second Quarter 2023 Net Revenues Increased 62% to $23.4 MillionLaunched VLN® Sales in California, Texas and FloridaDelivered Record GVB Ingredient Volumes as Dominant Supplier in North...
1.01-16x9-GVB-Biopharma-KK-123911 (1).png
22nd Century Group (XXII) Updates Second Quarter 2023 Results Webcast Time on August 14, 2023
09. August 2023 08:00 ET | 22nd Century Group, Inc
BUFFALO, N.Y., Aug. 09, 2023 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: XXII), a leading biotechnology company dedicated to improving health with reduced nicotine tobacco, hemp/cannabis...
1.01-16x9-GVB-Biopharma-KK-123911 (1).png
22nd Century Group (Nasdaq: XXII) to Announce Second Quarter 2023 Results on August 14, 2023
07. August 2023 08:00 ET | 22nd Century Group, Inc
BUFFALO, N.Y., Aug. 07, 2023 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: XXII), a leading biotechnology company dedicated to improving health with reduced nicotine tobacco, hemp/cannabis...
1.01-16x9-GVB-Biopharma-KK-123911 (1).png
22nd Century Announces Executive Leadership Changes
24. Juli 2023 09:20 ET | 22nd Century Group, Inc
Expands Board with New Highly Accomplished Independent Director Strengthens Balance Sheet and Implements $15 Million Cost Reduction Initiative BUFFALO, N.Y., July 24, 2023 (GLOBE...
1.01-16x9-GVB-Biopharma-KK-123911 (1).png
22nd Century Group (XXII) Regains Compliance with Nasdaq Listing Standards
20. Juli 2023 09:20 ET | 22nd Century Group, Inc
BUFFALO, N.Y., July 20, 2023 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: XXII), a leading biotechnology company focused on utilizing advanced plant technologies to improve health and...
1.01-16x9-GVB-Biopharma-KK-123911 (1).png
A Cigarette to Help Californians Smoke Less: 22nd Century Group, Inc. Launches Reduced Nicotine VLN® King Cigarettes in California, VLN Will Be Sold at #1 U.S. Convenience Store Chain and Other Responsible Retail Locations
17. Juli 2023 09:20 ET | 22nd Century Group, Inc
SACRAMENTO, Calif., July 17, 2023 (GLOBE NEWSWIRE) -- Biotech company 22nd Century Group, Inc. (NASDAQ: XXII) this week launched VLN® King cigarettes, the first-ever reduced nicotine combustible...
1.01-16x9-GVB-Biopharma-KK-123911 (1).png
22nd Century Group (XXII) VLN® Products Now Selling in Montana C-Stores
13. Juli 2023 08:40 ET | 22nd Century Group, Inc
Town Pump, #1 Chain in Montana, Selling VLN® Products in More Than 80 Stores Across the State Broad Availability of VLN® Expands Access to New Tool to Reduce the Harms of Smoking BUFFALO, N.Y., July...
1.01-16x9-GVB-Biopharma-KK-123911 (1).png
22nd Century Group (XXII) Announces New Agreement with Hub, Inc. to Expand Midwest Distribution
12. Juli 2023 08:35 ET | 22nd Century Group, Inc
BUFFALO, N.Y., July 12, 2023 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: XXII), a leading biotechnology company focused on utilizing advanced plant technologies to improve health and...